Microbot Medical's LIBERTY pivotal study published in JVIR; full market launch in April 2026

Microbot Medical Inc.

ACCESS-PVI study published in JVIR, a top radiology journal, after independent peer review.
LIBERTY received FDA clearance in Sep 2025; limited market release started late 2025.
Full commercial launch planned at SIR conference in April 2026 to expand adoption.
Dr. Francois Cornelis, first author, was Lead PI for the multicenter feasibility study.
LIBERTY is first FDA-cleared single-use robotic system for peripheral endovascular procedures.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.